CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 14 enrolled
Drug / intervention
Triheptanoindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02018315
NCT02018315Phase 1Completed
CompareCT.gov

Clinical Trial of Citric Acid Cycle Stimulation in Energy-deficiency States: Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) (NMTUT 2010B)

Juan Pascual·interventional·Posted Dec 23, 2013·Updated Oct 31, 2019

In Brief

A Phase 1 clinical trial evaluating Triheptanoin for Glucose Transporter Type 1 Deficiency Syndrome and GLUT1 Deficiency Syndrome. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The purpose of this trial is to determine if an alternative energy source will impact brain metabolism in a disorder characterized by glucose metabolism failure in the brain. The central hypothesis tested in this investigation is whether circumventing impaired glucose metabolism is feasible, safe and potentially promising by supplying anaplerotic precursors through metabolism of odd-carbon fatty acids that can enter the citric acid cycle (CAC) through alternative metabolic pathways.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlucose Transporter Type 1 Deficiency Syndrome, GLUT1 Deficiency Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 23, 2013
Enrollment StartJan 1, 2012
Primary CompletionJan 1, 2013
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.5 years ago

Interventions

Triheptanoindrug

Triheptanoin is a 7-carbon medium chain triglyceride